


CLAIMS

1. A compound of Formula (I)



or a pharmaceutically acceptable salt thereof, wherein,

ring vertex A¹ is selected from the group consisting of N, CH, C(O) and C(R⁴);

ring vertex A² is selected from the group consisting of N, CH, and C(R⁴);

each of ring vertices A³, A⁴, A⁵ and A⁶ is independently selected from the group consisting of CH and C(R⁴);

each of the dashed bonds independently indicate a single or double bond;

R¹ is selected from the group consisting of -C₁₋₈ alkylene-heteroaryl, -C₁₋₈ alkylene-C₆₋₁₀ aryl,

C₁₋₈ alkyl, C₁₋₈ haloalkyl, -C(O)-C₁₋₈ alkyl, -C(O)-C₆₋₁₀ aryl, -C(O)-heteroaryl,

-C(O)-C₃₋₆ cycloalkyl, -C(O)-heterocycloalkyl, -C(O)NR^{1a}R^{1b}, -SO₂-C₆₋₁₀ aryl,

-SO₂-heteroaryl, -C(O)-C₁₋₈ alkylene-O-heteroaryl, -C(O)-C₁₋₈ alkylene-O-C₆₋₁₀ aryl, -

C(O)-C₁₋₈ alkylene-O- heterocycloalkyl, -C(O)-C₁₋₈ alkylene-O- C₃₋₆ cycloalkyl, -

C(O)-C₁₋₈ alkylene-heteroaryl, -C(O)-C₁₋₈ alkylene- C₆₋₁₀ aryl,

-C(O)-C₁₋₈ alkylene-heterocycloalkyl, -C(O)-C₁₋₈ alkylene-C₃₋₆ cycloalkyl and

-CO₂R^{1a}; the heterocycloalkyl is a 4 to 8 membered ring having from 1 to 3

heteroatoms as ring vertices selected from N, O and S; and the heteroaryl group is a 5

to 10 membered aromatic ring having from 1 to 3 heteroatoms as ring vertices

selected from N, O and S;

wherein R^{1a} and R^{1b} are each independently selected from the group consisting of hydrogen,

C₁₋₈ alkyl, and C₁₋₈ haloalkyl;

wherein R¹ is optionally substituted with 1 to 5 R⁵ substituents;

R^{2a} and R^{2c} are each independently selected from the group consisting of C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} haloalkyl, $-O-C_{1-6}$ haloalkyl, $-S-C_{1-6}$ alkyl, $-C_{1-6}$ alkyl- $O-C_{1-6}$ alkyl, $-C_{1-6}$ alkyl- $S-C_{1-6}$ alkyl, CN, and halogen;

R^{2b} , R^{2c} , and R^{2d} are each independently selected from the group consisting of hydrogen, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} haloalkyl, $-O-C_{1-6}$ haloalkyl, $-S-C_{1-6}$ alkyl, $-C_{1-6}$ alkyl- $O-C_{1-6}$ alkyl, $-C_{1-6}$ alkyl- $S-C_{1-6}$ alkyl, cyano, and halogen;

each R^3 is independently selected from the group consisting of C_{1-6} alkyl, C_{1-6} haloalkyl, halogen and hydroxyl, and optionally two R^3 groups on the same carbon atom are combined to form oxo ($=O$) or to form a three to five membered cycloalkyl ring;

each R^4 is independently selected from the group consisting of C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} hydroxyalkyl, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, $-O-C_{1-6}$ haloalkyl, halogen, cyano, hydroxyl, $-S-C_{1-6}$ alkyl, $-C_{1-6}$ alkyl- $O-C_{1-6}$ alkyl, $-C_{1-6}$ alkyl- $S-C_{1-6}$ alkyl, $-NR^{4a}R^{4b}$, $-CONR^{4a}R^{4b}$, $-CO_2R^{4a}$, $-COR^{4a}$, $-OC(O)NR^{4a}R^{4b}$, $-NR^{4a}C(O)R^{4b}$, $-NR^{4a}C(O)_2R^{4b}$, and $-NR^{4a}-C(O)NR^{4a}R^{4b}$;


each R^{4a} and R^{4b} is independently selected from the group consisting of hydrogen, C_{1-4} alkyl, and C_{1-4} haloalkyl;

each R^5 is independently selected from the group consisting of C_{1-8} alkyl, C_{1-8} alkoxy, C_{1-8} haloalkyl, C_{1-8} haloalkoxy, C_{1-8} hydroxyalkyl, $-C_{1-8}$ alkylene-heterocycloalkyl, $-C_{1-8}$ alkylene- C_{3-6} cycloalkyl, C_{3-6} cycloalkyl, heterocycloalkyl, halogen, OH, C_{2-8} alkenyl, C_{2-8} alkynyl, CN, $C(O)R^{5a}$, $-NR^{5b}C(O)R^{5a}$, $-CONR^{5a}R^{5b}$, $-NR^{5a}R^{5b}$, $-C_{1-8}$ alkylene- $NR^{5a}R^{5b}$, $-S-C_{1-6}$ alkyl, $-C_{1-6}$ alkylene- $O-C_{1-6}$ alkyl, $-C_{1-6}$ alkylene- $S-C_{1-6}$ alkyl, $-OC(O)NR^{5a}R^{5b}$, $-NR^{5a}C(O)_2R^{5b}$, $-NR^{5a}-C(O)NR^{5b}R^{5b}$, and CO_2R^{5a} ; wherein the heterocycloalkyl group is a 4 to 8 membered ring having from 1 to 3 heteroatoms as ring vertices selected from N, O, and S;

wherein each R^{5a} and R^{5b} is independently selected from the group consisting of hydrogen, C_{1-8} alkyl, and C_{1-8} haloalkyl, or when R^{5a} and R^{5b} are attached to the same nitrogen atom they are combined with the nitrogen atom to form a 5 or 6-membered ring having from 0 to 1 additional heteroatoms as ring vertices selected from N, O, or S; and


the subscript n is 0, 1, 2 or 3.

2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the ring portion having A¹, A², A³, A⁴, A⁵, and A⁶ as ring vertices is a bicyclic heteroaryl selected from the group consisting of



wherein m is 0, 1, 2 or 3; and wherein the R⁴ substituents may be attached to any suitable carbon ring vertex of the bicyclic heteroaryl.

3. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the ring portion having A¹, A², A³, A⁴, A⁵, and A⁶ as ring vertices is a bicyclic




heteroaryl represented by the structure


wherein m is 0, 1, 2, or 3; and wherein the R⁴ substituents may be attached to any suitable carbon ring vertex of the bicyclic heteroaryl.

4. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein each R⁴ is independently selected from the group consisting of C₁₋₄ alkyl, C₁₋₄ alkoxy, C₁₋₆ hydroxyalkyl, halogen, cyano, and -CO₂R^{4a}; and wherein the R⁴ substituents may be attached to any suitable carbon ring vertex of the bicyclic heteroaryl.

5. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the ring portion having A¹, A², A³, A⁴, A⁵, and A⁶ as ring vertices is a bicyclic heteroaryl selected from the group consisting of:



6. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the ring portion having A¹, A², A³, A⁴, A⁵, and A⁶ as ring vertices is a bicyclic heteroaryl selected from the group consisting of:



7. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R¹ is selected from the group consisting of -C₁₋₈ alkylene-heteroaryl, -C₁₋₈ alkylene-C₆₋₁₀ aryl, C₁₋₈ alkyl, C₁₋₈ haloalkyl, -C(O)-C₁₋₈ alkyl, -C(O)-C₆₋₁₀ aryl, -C(O)-heteroaryl, -C(O)-C₃₋₈ cycloalkyl, -C(O)NR^{1a}R^{1b}, -SO₂-C₆₋₁₀ aryl, -C(O)-C₁₋₈ alkylene-O-C₆₋₁₀ aryl, and -CO₂R^{1a}; wherein the heterocycloalkyl is a 4 to 8 membered ring having from 1 to 3 heteroatoms as ring vertices selected from N, O and S; and the heteroaryl group is a 5 to 10 membered aromatic ring having from 1 to 3 heteroatoms as ring vertices selected from N, O and S; and wherein R^{1a} and R^{1b} are each independently selected from the group consisting of hydrogen, C₁₋₈ alkyl, and C₁₋₈ haloalkyl; and R¹ is optionally substituted with 1 to 5 R⁵ substituents.


1 **8.** The compound of claim 1, or a pharmaceutically acceptable salt thereof,
 2 wherein each R^5 is independently selected from the group consisting of C_{1-8} alkyl, C_{1-8} alkoxy,
 3 C_{1-8} haloalkyl, C_{1-8} haloalkoxy, C_{1-8} hydroxyalkyl, C_{3-6} cycloalkyl, halogen, OH, $-NR^{5a}R^{5b}$, and
 4 CO_2R^{5a} , wherein each R^{5a} and R^{5b} is independently selected from the group consisting of
 5 hydrogen, C_{1-8} alkyl, and C_{1-8} haloalkyl.


1 **9.** The compound of claim 1, or a pharmaceutically acceptable salt thereof,
 2 wherein R^1 is $-CH_2$ -phenyl optionally substituted by 1 to 3 R^5 .

1 **10.** The compound of claim 1, or a pharmaceutically acceptable salt thereof,
 2 wherein R^1 is $-CH_2$ -phenyl substituted by 1 or 2 R^5 , wherein each R^5 is independently C_{1-4}
 3 haloalkyl.


1 **11.** The compound of claim 1, or a pharmaceutically acceptable salt thereof,
 2 wherein R^1 is $-CH_2$ -phenyl substituted by 1 or 2 CF_3 .

1 **12.** The compound of claim 1, or a pharmaceutically acceptable salt thereof,
 2 wherein R^1 is selected from the group consisting of





1 **13.** The compound of claim 1, or a pharmaceutically acceptable salt thereof,



1 **14.** The compound of claim 1, or a pharmaceutically acceptable salt thereof,
2 wherein R^{2b} , R^{2c} , and R^{2d} are each H.


1 **15.** The compound of claim 1, or a pharmaceutically acceptable salt thereof,
2 wherein R^{2a} and R^{2e} are each independently selected from the group consisting of C_{1-6} alkyl and
3 C_{1-6} haloalkyl.



1 **16.** The compound of claim 1, or a pharmaceutically acceptable salt thereof,
2 wherein R^{2a} and R^{2e} are each independently C_{1-6} alkyl.

1 **17.** The compound of claim 1, or a pharmaceutically acceptable salt thereof,
2 wherein R^{2a} and R^{2e} are each independently selected from the group consisting of methyl and
3 ethyl.

1 **18.** The compound of claim 1, or a pharmaceutically acceptable salt thereof,
2 wherein R^{2a} and R^{2e} are both methyl or are both ethyl.

1 **19.** The compound of claim 1, or a pharmaceutically acceptable salt thereof,





2 wherein  is selected from the group consisting of

3  and .


1 **20.** The compound of claim 1, or a pharmaceutically acceptable salt thereof,
2 wherein n is 0, 1 or 2.

1 **21.** The compound of claim 1, or a pharmaceutically acceptable salt thereof,
2 wherein each R³ is independently C₁₋₄ alkyl.


1 **22.** The compound of claim 1, or a pharmaceutically acceptable salt thereof,

2 wherein  is selected from the group consisting of , , and
3 .


1 **23.** The compound of claim 1, or a pharmaceutically acceptable salt thereof,
2 having a structure represented by Formula (Ia), (Ib) or (Ic):



(Ia)




(Ib)




(Ic).


24. The compound of claim 2, or a pharmaceutically acceptable salt thereof, having a structure represented by Formula (Id), (Ie), or (If):



(Id)





(Ie)



(If)

wherein m is 0, 1 or 2; wherein the R⁴ substituents may be attached to any suitable carbon ring vertex of the bicyclic heteroaryl; and wherein p is 0, 1 or 2.

25. The compound of claim 2, or a pharmaceutically acceptable salt thereof, having a structure represented by Formula (Ig) or (Ih):



4

(Ig)

(Ih)

5

wherein m is 0, 1 or 2 and wherein the R⁴ substituents may be attached to any

6


suitable carbon ring vertex of the indole heteroaryl.

1

26. The compound of claim 1, or a pharmaceutically acceptable salt thereof,


2

wherein said compound is selected from the group consisting of




3

,




,




4

,




,




5

,




,




6

,



,


7



,

,


8



,

,


9



,

,


10



,






,

11




,


,




2




,




2




,




,



17




,




,

18




,




,

19




,




,

20




,




,

21




,



,


22



,

,


23



,

,


24



,

,


25



,






,



26



,

,







27

, and

.



- 1 **27.** The compound of claim 1, or a pharmaceutically acceptable salt thereof,
 2 wherein said compound is selected from the group consisting of



3

,

,




4

, and


.

- 1 **28.** The compound of claim 1, or a pharmaceutically acceptable salt thereof,
 2 wherein said compound is selected from the group consisting of




3

1 **29.** The compound of claim 1, or a pharmaceutically acceptable salt thereof,
 2 wherein said compound is



3

1 **30.** The compound of claim 1, or a pharmaceutically acceptable salt thereof,
 2 wherein said compound is



3

1 **31.** The compound of claim 1, or a pharmaceutically acceptable salt thereof,
 2 wherein said compound is

